Neuronal Replacement in Stem Cell Therapy for Stroke: Filling the Gap

Introduction

Ischemic stroke leads to neuronal loss due to shortage of glucose and oxygen supply to an area of the brain, being one of the leading causes of death and adult disability worldwide. The mechanical thrombectomy and pharmacological thrombolysis are the only approved treatments, which are focused on the elimination of the clogging agents in the acute phase after the insult (up to 6 h), making only this fraction of patients eligible for treatment. Unfortunately, nowadays there are virtually no treatments to support efficient recovery of impaired sensory, motor, and cognitive deficits in stroke-surviving patients and more than half of them remain disabled to various degree. Therefore, there is a high demand on new strategies that will support the spontaneously occurring regeneration of damaged neuronal tissue and lead to a more efficient long-term recovery.

In this regard, transplantation of specific types of neuronal precursors/progenitors is an emerging and promising therapy for stroke patients, which has been pioneered in the treatment of Parkinson Disease (PD) using dopaminergic neurons from aborted human fetuses (Lindvall et al., 1990; Kordower et al., 1998). Many studies using animal models mimicking different neurological conditions with brain damage have shown that stem cell-based treatment might improve recovery through two types of action mode. First mode, the so-called bystander effect, is proposed to be caused by release of different factors leading to immunomodulation, reduction of brain-blood-barrier damage (Eckert et al., 2015), stimulation of angiogenesis, endogenous neurogenesis, and neuronal plasticity (Chang et al., 2013; Mine et al., 2013). The second mode is based on cell replacement and justified by recent publications demonstrating the ability of grafted pluripotent stem cells (PSCs) to morphologically differentiate into different types of neurons, establish synaptic connections with the host circuitry and get integrated in damaged neuronal network (Grade and Gotz, 2017).

Bystander effect, the first action mode, could only have moderate effect on the improvement of spontaneous regeneration through modulation of tissue environment. This could be even less effective in the brain of elderly patients, which represent the majority of the ones suffering stroke, due to a decreased cellular plasticity and self-repair capacity. On contrary, supporting brain with young neurons for replacement of dead or damaged ones could be more efficient mode of action and might lead to better, long-term and sustainable recovery of impaired functions.

At the end of the 90’s, the capacity to isolate and culture human embryonic stem cells (ESCs) (Thomson et al., 1998), opened the possibility to generate more easily and robustly specific neuronal subtypes for regenerative medicine, avoiding several problems related to the use of human fetal tissue. One decade later, thanks to the advent of cell reprogramming technology, human adult somatic cells (i.e., skin cells) can be converted into induced PSCs (iPSCs) (Yamanaka, 2007), allowing generation of patient-specific neurons. The use of human iPSCs for cell therapy avoids need for long immunosuppressive treatments, risk of graft rejection and ethical concerns related to the use of human embryos. In this regard, it has been recently shown that dopaminergic progenitors derived from clinical-grade human ESC or iPSC lines are safe and effective for cell-based therapy in PD (Doi et al., 2020; Kim et al., 2020). Most importantly, human iPSC transplantation into the putamen of a PD patient suggested graft survival as well as improvement of PD symptoms at 18–24 months after surgery (Schweitzer et al., 2020). These encouraging results motivate the use of cell replacement strategy not only for PD but also for other neurological disorders such as stroke. In contrast to PD, stroke affects different neuronal cell types depending on the size and the location of the injury, which has required the development of very specific differentiation protocols to generate the adequate cell population for transplantation (Alia et al., 2019). Besides this, new technological tools have allowed the confirmation of neuronal replacement after transplantation of different kinds of PSC-derived neural precursors into the damaged brain as is summarized in the present review. These advances bring stem cell therapy closer to a clinical application for stroke patients.

By the Hands of Technology

Solid evidence demonstrating that graft-derived neurons can functionally integrate in host brain circuitry has been closely related to the development of new technological tools. Monosynaptic tracing of neurons using rabies virus, control and monitoring of neuronal activity by optogenetic technology and recording of intracellular calcium levels, respectively, together with more “traditional” techniques such as electron microscopy or electrophysiological recordings, allowed thorough study of functional connectivity between grafted and host neurons (Figure 1).

Figure 1. Schematic summary of the technological approaches used to study the functional connectivity between grafted and host neurons. Transplanted cells (colored in green) are located adjacent to the cortical ischemic lesion. For clarity and as an example, thalamo-cortical afferent projections to the graft and transcallosal projections from graft to host cortical neurons in the contralateral hemisphere are presented. Different techniques are distributed in the areas of the brain where they are applied: (A) contralateral cortex, (B) transplant, (C) thalamus. TX, transplant; CC, corpus callosum.

Rabies virus has the ability to spread transynaptically between neurons. The connected neurons can be genetically targeted using tracing vectors with neuronal promoters and receptors for specific viral envelopes (Wickersham et al., 2007). Pseudotyped rabies virus carrying fluorescent dyes can be used for identifying either cells with presynaptic connection to grafted cells (Grealish et al., 2015; Tornero et al., 2017) or brain areas where host neurons have received synaptic contacts from the grafted neurons (Palma-Tortosa et al., 2020). New improved methods for brain tissue clearing, such as iDISCO or CUBIC, have given the possibility to perform fluorescence imaging in 3D stained tissue, preserving anatomical structures in whole brain or a portion of it, allowing the detection of graft projections and monosynaptic input maps without the need for less accurate sectioning and further reconstruction of the tissue (Doerr et al., 2017). Unfortunately, the resolution of these imaging techniques does not allow visualization of projections or connections at the level of individual cell, but they have shown great potential for a general overview of the distribution of cells and their axonal projections.

Once the location of host neurons innervating grafted cells is detected, functionality of their connections can be addressed using traditional extracellular electrophysiological recordings in alive anesthetized animals in response to afferent stimulation (Tornero et al., 2017). As an alternative, optogenetic tools have been used to modify electrophysiological properties of specific set of neurons that express opsin proteins sensitive to light of particular wavelength (Cheng et al., 2014). Similarly, the so-called DREADDs (from designer receptors exclusively activated by designer drugs), uses inert chemical ligands to activate or inhibit neuronal activity (Armbruster et al., 2007). These last two strategies can be combined with in vivo electrophysiology as well as with patch-clamp in acute slices to confirm functional synaptic connectivity between host neurons and grafted cells. Moreover, silencing of grafted cells using optogenetic or DREADD tools allowed to assess the contribution of its neuronal activity to functional recovery (Palma-Tortosa et al., 2020), while the stimulation of graft-derived neurons using a combination of optogenetics and DREADDs (optochemogenetic) can be used to improve its functional integration into the host circuitry (Yu et al., 2019).

On the other hand, calcium imaging using genetically encoded calcium indicators (GECIs) allows quantitative monitoring of neuronal activity in alive animals while exposing them to sensory stimulus (Falkner et al., 2016; Linaro et al., 2019). Together with two-photon microscopy, GECIs enable single cell and high temporal resolution in a three-dimensional framework. Moreover, this approach allows evaluation at multiple time-points using cranial window in the skull of the animals, making it possible to track dynamics of functional integration of grafted neurons. This strategy is limited to monitoring superficial cortical layers, even though technology is advancing rapidly to achieve devices that allow the visualization of deeper areas of the brain.

In the same line, bioluminescence reporters are also a validated method for non-invasive monitoring of grafted cells (Vogel et al., 2019). Despite lower spatial resolution of in vivo bioluminescence imaging as compared with calcium imaging, the use of cell-type specific promoters allows the study of cell therapy in animal models. Although this strategy does not provide information about neuronal functional integration, it has shown much potential for the study of the maturation of the different cell types generated by the transplant.

The development of all these techniques has boosted the studies on neuronal replacement after transplantation of PSC-derived cells into the damaged brain, allowing to obtain qualitatively new data for the assessment of this approach in future clinical settings.

Cell Replacement

Several decades ago, human fetal grafts, enriched with dopaminergic progenitors and transplanted in the striatum of PD patients showed good survival and capacity to improve motor function (Lindvall et al., 1990). The visualization of the graft in post-mortem samples two decades later showed a remarkable level and specificity of circuit integration in the host brain (Li et al., 2016). This was the first solid evidence that functional restoration of damaged neuronal circuitry might be possible using human PSC transplantation. From that moment, the transplantation of PSCs as therapy for other brain disorders, such as ischemic stroke, has progressed from demonstrating high level of specificity when neurons integrate into the damaged circuits, to the confirmation of grafted-cell contribution to functional recovery (studies summarized in Table 1).

Table 1. Summary of the studies exploring cell replacement occurrence in stem cell therapy for brain damage (organized in chronological order).

PSC-derived progenitors transplanted in different animal models of brain damage have proven to differentiate into specific neuronal subtypes and integrate into the host brain circuitry. Moreover, a strong association between graft integration and functional restoration, evidencing the importance of areal-identity match for successful repair, has been shown by several groups (Espuny-Camacho et al., 2018; Terrigno et al., 2018; Xiong et al., 2021). Given this, substantial progress has been made in optimizing protocols for the generation of scalable cell populations produced under standardized and quality-controlled conditions for future therapeutic use (Steinbeck and Studer, 2015). Most commonly used protocols for neuralization of human ESCs or iPSCs combine small-molecule inhibitors of bone morphogenic protein (BMP) and TGFβ/activin/nodal signals (Morizane et al., 2011; Qi et al., 2017). This step may or not imply the formation of embryoid bodies, and resulting cells acquire rosette-like morphology (Falk et al., 2012) similar to neuroepithelial cells of the brain. Then, specification of neuronal cell subtypes requires a timed addition of other pattering factors that activate or inhibit master developmental pathways (Petros et al., 2011).

Both, ESC- or iPSC-derived cortical neurons transplanted into the peri-infarct region of damaged visual cortex have been demonstrated to develop a pattern of connectivity similar to endogenous neurons from this area of the brain (Michelsen et al., 2015; Falkner et al., 2016; Espuny-Camacho et al., 2018; Green et al., 2018). Functional studies performed in the same scenario using calcium imaging revealed that grafted neurons were able to respond to specific visual stimuli (Falkner et al., 2016). Supporting the formation of functional afferent connections, iPSC and ESC-derived grafted neurons transplanted into the somatosensory injured cortex after ischemic stroke or specific ablation of layer II and III, respectively, were able to respond to optogenetic activation of thalamic afferent axons as well as to physiological sensory stimuli (Tornero et al., 2017; Andreoli et al., 2020).

Similar results have been found when the transplantation was performed in intact animals. Interestingly, graft-derived neurons with a specific identity (i.e., hippocampal, cortical, or striatal) project to the same target areas than host neurons with the same identity (Doerr et al., 2017; Terrigno et al., 2018). Most importantly, grafted cells display similar activity and tuned responses to sensory stimuli resembling host neurons (Linaro et al., 2019). Also, in animal models affecting other areas of the central nervous system, such as spinal cord injury, it has been shown that transplantation of human iPSC-derived neuronal progenitors gives rise to an improved recovery with functional integration of grafted cells (Nori et al., 2011; Lu et al., 2012).

Convincing demonstration of neuronal replacement should also include evidences of the establishment of functional efferent connections from grafted cells to the neurons of appropriate host brain structures. In this regard, rabies virus monosynaptic tracing has shown that iPSC-derived progenitors transplanted into the somatosensory damaged cortex formed functional efferent synaptic inputs with host neurons located in the contralateral somatosensory cortex (Palma-Tortosa et al., 2020). Importantly, grafted cells traced with rabies virus were positive for specific markers of transcallosal projection neurons located in the healthy cortex. In addition, studies with electron microscopy showed that graft-derived axons exhibited ultrastructural features similar to those of host axons as well as different degrees of myelination by host oligodendrocytes. Regarding the contribution of transplanted iPSC-derived progenitors in the animal motor performance, optogenetic inhibition of the graft-derived neurons at 6 months after transplantation reduced the mobility of both paws in the animals, demonstrating that the graft became part of the host circuitry participating in the physiological motor behavior (Palma-Tortosa et al., 2020).

With the aim of maximizing functional recovery and integration of grafted cells, it has been demonstrated that specific activation of graft-derived neurons by using opto- or chemogenetics induces a considerable improvement including increased neurite outgrowth and synaptic plasticity, upregulation of synaptic proteins, promotion of neuronal differentiation and axonal remyelination (Yu et al., 2019; Andreoli et al., 2020). In the same line, the use of hydrogels functionalized for a laminin-derived epitope mimicking brain extracellular matrix, improves neuronal differentiation and functional electrophysiological properties of human ESC-derived cortical neurons transplanted in an animal stroke model (Somaa et al., 2017). Moreover, loading those hydrogels with brain-derived neurotrophic factor (BDNF), grafted ESC-derived neurons showed enhanced long-term survival and vascularization as well as reduced secondary degeneration of host cortex in the same model (Nisbet et al., 2018).

However, even giving the importance of these studies, they have all been conducted using xenotransplantation of human cells in animal models of neurological disorders. Addressing this issue, recent publication from our group has demonstrated that human iPSC-derived cortical progenitors transplanted into human adult cortical tissue, not only survive and give rise to mature cortical neurons, but also exhibit electrophysiological and ultrastructural properties of functional neurons and establish afferent and efferent synaptic connections with the host human cortical neurons, as evidenced by both, rabies virus monosynaptic tracing and electron microscopy (Gronning Hansen et al., 2020). This is the first evidence that human PSCs can integrate into adult human neural network and supports the potential clinical use of PSCs to restore neuronal damaged network in patient with brain disorders.

Concluding Remarks and Future Perspectives

Since the potential use of stem cell therapy in stroke patients was suggested for improved recovery of functional deficits, many efforts have been made for better understanding of the mechanisms behind its beneficial effects (Grade and Gotz, 2017; Kokaia et al., 2017). During the last 5 years, several studies with transplantation of stem cell-derived neural progenitors in animal models of different kinds of brain damage have shown the generation of specific synaptic contacts from host to graft and vice versa that are able to send relevant information. These studies highlight the importance of cell specification to generate the very exact subtype of neuronal identity for reconstruction of each brain area. Another limitation for the clinical application of cell-based treatments is that extensive in vitro expansion of cellular products is associated with increased genomic and epigenomic instability, urging for standardized cell culture settings to minimize genomic alterations.

In this respect, our group has recently demonstrated using rat stroke model and long-term neuroepithelial-like cells from human origin that neuronal activity from grafted cells participate in the maintenance of normal motor function, allegedly contributing to the improved recovery of the animals (Palma-Tortosa et al., 2020). Moreover, our recent study using organotypic cultures of adult human cortex showed that similar integration occurs also in a human-to-human transplantation setting (Gronning Hansen et al., 2020).

This progress brings stem cell therapy closer to its clinical application for stroke patients. However, further experimental research will be needed to develop protocols for the generation of the optimum cell type with the aim of inducing maximum recovery. Some work has been already done at this level in the context of the generation of dopaminergic progenitors for the treatment of PD (Doi et al., 2020; Kim et al., 2020). Due to the high cost of production of patient-specific cells for regenerative therapies, the future strategies, most likely will be based in human leukocyte antigen (HLA)-typed iPSCs or engineered “universal” ESC lines, to avoid need for immunosuppression (Doi et al., 2020; Piao et al., 2021). Currently, the idea of generating cell banks from which therapeutic products can be derived and matched immunologically to patients has been already proposed (Sullivan et al., 2020; Takahashi, 2020).

To move toward future clinical trials, it would be critical to develop the proper strategy for the selection of stroke patients based on the location and the size of the ischemic lesion, since this can determine the efficacy of the treatment. It should be also pointed out that stroke patients are in most of the cases elderly people, which might influence the ability of the transplanted cells to exert recovery-promoting effects. One should be aware, that data obtained using animal models may not necessarily translate into meaningful effects in a clinical setting. Baring this in mind, now we need to explore in parallel with more investigative basic research in order to maximize the efficacy of the therapy. Stem cell therapy has approached a very exciting stage, and clinical translation should consider the critical scientific, regulatory and ethical issues, in a collaborative way between basic scientist and clinicians.

Author Contributions

SP-T, BC-S, ZK, and DT wrote the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades and European Regional Development Fund (ERDF) [RETICS (Red de Terapia Celular; RD16/0011/0012)], Spain; European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 813851; University of Barcelona; Swedish Research Council, and Swedish Brain Foundation.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We thank Bengt Mattsson for illustration.

References